Max Healthcare

Which are the latest news on Max Healthcare?

Why is Max Healthcare Institute Ltd falling/rising?

As of 05-Sep, Max Healthcare Institute Ltd's stock is declining, down 0.93% with a significant yearly return of -15.18%. Contributing factors include negative quarterly results, low operating profit to interest ratio, and high valuation concerns despite increased investor participation.

As of 05-Sep, Max Healthcare Institute Ltd's stock price is currently falling, with a change of -9.2, representing a decrease of 0.93%. This decline is reflected in the stock's performance over various time periods, showing a 1-week drop of 2.77% and a 1-month decrease of 7.86%. Over the past year, the stock has underperformed significantly, with a return of -15.18%, compared to a market return of 1.51% for the BSE500 index.<BR><BR>Several factors contribute to this downward trend. The company reported negative results for the quarter ending June 26, with a decline in profit after tax (PAT) by 12.8% compared to the previous four-quarter average. Additionally, the operating profit to interest ratio is at its lowest, indicating potential challenges in servicing debt, despite the company having a low Debt to EBITDA ratio of 1.55 times.<BR><BR>Moreover, the stock is trading below its moving averages across multiple time frames, suggesting a bearish trend. Although there has been a rise in investor participation, with delivery volume increasing by 81.49% against the 5-day average, the overall performance and valuation metrics indicate that the stock is perceived as expensive, with a PEG ratio of 2.7. This combination of negative financial results, underperformance relative to the market, and high valuation concerns are driving the stock price lower.

Who are in the management team of Max Healthcare?

The management team of Max Healthcare includes Chairman Abhay Soi, Non-Executive Directors Anil Bhatnagar and Narayan Seshadri, and several Independent Non-Executive Directors: K Narasimha Murthy, Mahendra Lodha, Michael Thomas Neeb, Pranav Amin, and Amrita Gangotra. This diverse team provides a blend of executive leadership and independent oversight.

The management team of Max Healthcare includes the following individuals:<BR><BR>1. **Abhay Soi** - Chairman / Executive Director<BR>2. **Anil Bhatnagar** - Non-Executive & Non-Independent Director<BR>3. **K Narasimha Murthy** - Independent Non-Executive Director<BR>4. **Mahendra Lodha** - Independent Non-Executive Director<BR>5. **Michael Thomas Neeb** - Independent Non-Executive Director<BR>6. **Pranav Amin** - Independent Non-Executive Director<BR>7. **Amrita Gangotra** - Independent Non-Executive Director<BR>8. **Narayan Seshadri** - Non-Executive Director<BR><BR>This team brings a mix of executive and independent oversight to the company. If you have any more questions about Max Healthcare or its operations, feel free to ask!

What does Max Healthcare do?

Max Healthcare Institute Ltd is a mid-cap company in the hospital industry, reporting net sales of ₹2,366 Cr and a net profit of ₹323 Cr for June 2026. Key metrics include a P/E ratio of 66.00, a dividend yield of 0.20%, and a market cap of ₹97,795 Cr.

Overview:<BR>Max Healthcare Institute Ltd operates in the hospital industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was originally incorporated in 2001 as "Infinitum Technologies Private Limited" in New Delhi, India. It changed its name to "Max Healthcare Institute Private Limited" in 2002 and subsequently to "Max Healthcare Institute Limited" later that same year. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,366 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 323 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 97,795 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 66.00<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.20%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 13.79%<BR>- Price to Book: 9.17<BR><BR>Contact Details:<BR>No Company Details Available. Address, phone, email, and website are not provided.

Who are the peers of the Max Healthcare?

Max Healthcare's peers include Apollo Hospitals, Fortis Health, Aster DM Quality, Global Health, Narayana Hrudaya, Krishna Institute, Dr. Agarwal's Health, and Rainbow Child. In terms of performance, Aster DM Quality leads with a 25.77% return, while Max Healthcare has the lowest at -11.72%.

Peers: The peers of Max Healthcare are Apollo Hospitals, Fortis Health., Aster DM Quality, Global Health, Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, and Rainbow Child.<BR><BR>Quality Snapshot: Excellent management risk is observed at Apollo Hospitals, Global Health, Narayana Hrudaya, Krishna Institu., and Rainbow Child, while Average management risk is found at Max Healthcare and Dr Agarwal's Hea, and the rest. For growth, Excellent growth is noted at Apollo Hospitals, Max Healthcare, and Narayana Hrudaya, while Good growth is seen at Fortis Health., Dr Agarwal's Hea, and the rest. Below Average growth is present at Aster DM Quality and Krishna Institu., and the rest. In terms of Capital Structure, Excellent capital structure is noted at Max Healthcare and Global Health, while Average capital structure is found at Aster DM Quality, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aster DM Quality at 25.77%, while Max Healthcare has the lowest at -11.72%. Max Healthcare's 1-year return is significantly lower than that of its peers. Additionally, the peers with negative six-month returns are Max Healthcare and Fortis Health.

How big is Max Healthcare?

As of 31st August, Max Healthcare Institute Ltd has a market capitalization of 97,795.00 Cr, with recent Net Sales of 8,712.05 Cr and a Net Profit of 1,457.40 Cr.

As of 31st August, Max Healthcare Institute Ltd has a market capitalization of 97,795.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Max Healthcare reported Net Sales of 8,712.05 Cr and a Net Profit of 1,457.40 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 10,746.63 Cr and Total Assets totaling 17,184.45 Cr.

Should I buy, sell or hold Max Healthcare Institute Ltd?

Are Max Healthcare Institute Ltd latest results good or bad?

Max Healthcare Institute Ltd's latest results show strong operational performance with a net profit increase and revenue growth, but concerns about stock underperformance, rising interest expenses, and high valuations suggest caution for investors.

Max Healthcare Institute Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹342.22 crore for Q4 FY26, which is a 13.72% increase quarter-on-quarter (QoQ) and a 7.28% increase year-on-year (YoY). Revenue also saw growth, reaching ₹2,142.89 crore, up 3.65% QoQ and 12.21% YoY. Additionally, the operating margin improved to 28.30%, marking the highest quarterly margin in recent times.<BR><BR>However, there are significant concerns. The company's stock has underperformed compared to its sector peers, declining 11.09% over the past year while the hospital sector gained 19.53%. The rising interest expenses, which surged to ₹66.66 crore, and a high price-to-earnings ratio of 73x raise questions about the sustainability of its premium valuation. Furthermore, the Mojo Score of 42 out of 100 indicates a "SELL" rating, reflecting worries about expensive valuations and flat near-term financial trends.<BR><BR>In summary, while the operational performance shows strength, the financial structure and market sentiment suggest caution for investors.

When is the next results date for Max Healthcare Institute Ltd?

The next results date for Max Healthcare Institute Ltd is 05 February 2026.

The next results date for Max Healthcare Institute Ltd is scheduled for 05 February 2026.

Is Max Healthcare technically bullish or bearish?

As of December 4, 2025, Max Healthcare's trend has shifted to bearish with moderate strength, supported by bearish signals from the MACD, KST, and moving averages, despite some mixed signals on the monthly timeframe.

As of 4 December 2025, the technical trend for Max Healthcare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the weekly MACD and KST both showing bearish signals, along with daily moving averages confirming a bearish trend. The Bollinger Bands indicate a bearish outlook on the weekly timeframe, while the monthly indicators show a mix of mildly bearish and mildly bullish signals, suggesting some divergence. Overall, the bearish trend is reinforced by the recent price action, with a notable decline in the past week and month compared to the Sensex.

How has been the historical performance of Max Healthcare?

Max Healthcare has experienced substantial growth from Mar'20 to Mar'25, with net sales increasing from 1,059.03 Cr to 7,028.46 Cr, and profit after tax rising from 12.91 Cr to 1,075.88 Cr. Total assets grew from 3,973.66 Cr to 15,186.44 Cr, reflecting the company's successful expansion strategy.

Answer:<BR>Max Healthcare has shown significant growth in its historical performance, particularly in net sales, which increased from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. The total expenditure, excluding depreciation, grew from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) has similarly improved, climbing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax increased from 12.78 Cr in Mar'20 to 1,406.37 Cr in Mar'25. The profit after tax also saw a rise, reaching 1,075.88 Cr in Mar'25 compared to 12.91 Cr in Mar'20. The company's earnings per share (EPS) increased from 1.1 in Mar'20 to 11.07 in Mar'25, showcasing enhanced profitability per share. On the balance sheet, total assets grew from 3,973.66 Cr in Mar'20 to 15,186.44 Cr in Mar'25, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,459.00 Cr in Mar'25, although cash flow from investing activities showed a negative trend at -1,614.00 Cr.<BR><BR>Breakdown:<BR>Max Healthcare's financial performance has demonstrated remarkable growth over the years, particularly in net sales, which surged from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This growth in revenue is accompanied by a corresponding increase in total operating income, which reached 7,028.46 Cr in Mar'25, up from 1,059.03 Cr in Mar'20. The company's total expenditure also rose significantly, from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, reflecting the costs associated with scaling operations. Operating profit (PBDIT) has shown a strong upward trajectory, increasing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax improved from 12.78 Cr to 1,406.37 Cr in the same period. The profit after tax reached 1,075.88 Cr in Mar'25, a substantial increase from 12.91 Cr in Mar'20. The earnings per share (EPS) also rose significantly, indicating improved profitability for shareholders. On the balance sheet, total assets expanded from 3,973.66 Cr to 15,186.44 Cr, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr, reflecting the company's growth strategy. Additionally, cash flow from operating activities improved to 1,459.00 Cr in Mar'25, despite a negative cash flow from investing activities of -1,614.00 Cr, indicating ongoing investments in growth.

Who are the top shareholders of the Max Healthcare?

The top shareholders of Max Healthcare include Abhay Soi with 23.73%, Foreign Institutional Investors holding 54.74%, and mutual funds with 13.38%. The Government of Singapore is the largest public shareholder at 5.69%, while individual investors own 3.31%, with no pledged promoter holdings.

The top shareholders of Max Healthcare include a mix of institutional and individual investors. The largest shareholder is Abhay Soi, who holds 23.73% of the company. Foreign Institutional Investors (FIIs) are significant shareholders as well, collectively holding 54.74% of the shares, represented by 1020 FIIs. Additionally, mutual funds have a presence with 13.38% held across 33 schemes. The Government of Singapore is the highest public shareholder, owning 5.69%. Individual investors collectively hold 3.31% of the shares. Notably, there are no pledged promoter holdings.

Is Max Healthcare overvalued or undervalued?

As of October 29, 2021, Max Healthcare Institute Ltd. is considered very expensive with a PE ratio of 100.29, significantly higher than its peers, indicating it may be overvalued despite a 43% return over the past year compared to the Sensex's 7.55%.

As of 29 October 2021, the valuation grade for Max Healthcare Institute Ltd. moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE Ratio of 100.29, a Price to Book Value of 12.11, and an EV to EBITDA of 62.71. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Max Healthcare's valuation appears steep, as it has a higher PE ratio than many competitors in the healthcare sector. For instance, while Max Healthcare's PE stands at 100.29, other industry players typically exhibit lower ratios, indicating that investors may be paying a high price for expected growth that may not materialize. Notably, the company's stock has outperformed the Sensex over the past year, with a return of 43% compared to the Sensex's 7.55%, which may have contributed to the inflated valuation.

Has Max Healthcare declared dividend?

Max Healthcare Institute Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of August 23, 2024. The company has shown significant price appreciation over the years, particularly with a total return of 220.75% over three years.

Max Healthcare Institute Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 6.09%, with a dividend return of 0%, resulting in a total return of 6.09%.<BR><BR>For the 1-year period, the price return was 40.24%, the dividend return was 0.19%, leading to a total return of 40.43%.<BR><BR>Over the 2-year period, the price return was 122.44%, with a dividend return of 0.42%, culminating in a total return of 122.86%.<BR><BR>In the 3-year period, the price return reached 220.06%, while the dividend return was 0.69%, resulting in a total return of 220.75%.<BR><BR>For the 4-year period, the price return was 373.32%, with a dividend return of 0.98%, leading to a total return of 374.3%.<BR><BR>In the 5-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Max Healthcare has declared a dividend, which contributes to its total returns, particularly noticeable over longer periods. The company shows strong price appreciation, especially in the 3 to 4-year periods, despite lower dividend contributions.